Targeting the EGF Receptor for Ovarian Cancer Therapy

Table 1

FDA approved EGF receptor inhibitors.

Generic, brand name	Type	Mechanism	Clinical Dose Range (route)	Approved Tumors	Company
Gefitinib, IressaZD1839	Small molecule TKI	Inhibits intracellular EGFR tyrosine kinase phosphorylation	250 mg daily (oral)	Platinum and taxane resistant nonsmall cell lung cancer	Astra-Zeneca
Erlotinib, TarcevaOS-774CP-358774	Small molecule TKI	Inhibits intracellular EGFR tyrosine kinase phosphorylation	100 mg–150 mg daily (oral)	Nonsmall cell lung cancer, pancreatic cancer	OSI Pharmaceuticals/Genentech
Lapatinib, TYKERBGW 572016	Small molecule dual TKI, EGFR-1 and EGFR-2,	Inhibits heterodimerization and her1/her2 phosphorylation	1250 mg daily days 1–21 (oral)	Her2+breast cancer refractory to herceptin and chemo	Glaxo-Smith Kline
Cetuximab, ErbituxIMC-C225	Human/mouse chimeric MAb	Extracellular domain binding and ligand blockade	400 mg/m^2 load then 250 mg/m^2 weekly (IV)	Metastatic colorectal cancer, head, and neck	ImClone
Panitumamab, VectibixABX-EGF	Humanized MAb	Extracellular domain binding and ligand blockade	6 mg/kg every 14 days (IV)	Metastatic refractory colorectal cancer	Amgen/Abgenix